We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for West Pharmaceutical in Q3 Earnings?
Read MoreHide Full Article
West Pharmaceutical Services (WST - Free Report) is scheduled to release third-quarter 2024 results on Oct. 10, before the opening bell. In the last reported quarter, the company delivered an earnings miss of 14.12%. WST’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 6.44%.
Currently, the Zacks Consensus Estimate for revenues is pegged at $710.2 million, indicating a decline of 5% from the year-ago period’s level. The consensus mark for earnings is pinned at $1.51 per share, indicating a decline of 30.1% year over year.
Factors to Note
During the second quarter, West Pharmaceutical’s Proprietary Products segment sales were hurt by an elevated level of customer destocking across its business units. The trend is likely to have continued in the third quarter, pulling sales down. A weak pharma market and declining sales related to COVID-19 vaccines are expected to have contributed to the decline. The declining trend in the Generic market unit and the Biologics market unit is likely to have continued as well.
Product-wise, sales of Administrative Systems, FluroTec and Westar products, along with Daikyo Crystal Zenith components, are likely to have decreased during the soon-to-be-reported quarter.
WST witnessed a strong uptake of HVP components, which include self-injection, Envision components and NovaPure products in the second quarter. The trend is projected to have continued in the quarter to be reported, partially cushioning the sales decline in the segment.
The company is also expected to have witnessed a gross margin contraction in the aforementioned segment. This was likely due to an unfavorable mix of products sold (stemming from the demand for high-value products), production efficiencies and higher sales prices.
On its second quarter earnings call, WST lowered its top and bottom-line outlook for 2024 by more than 4% and 16%, respectively, as measured by the midpoint of the new and earlier guided ranges.
West Pharmaceutical Services, Inc. Price and EPS Surprise
WST’s Contract-Manufactured Products segment might have aided top-line growth due to expanding customer demand for its services during the quarter.
The company’s business is exposed to foreign currency exchange rate fluctuations, which are likely to have negatively impacted its third-quarter performance. Meanwhile, WST is investing in capacity expansion, especially to support its HVP products. This is likely to have driven cash burn during the soon-to-be-reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for WST this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is -0.16%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #4 (Sell) at present.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
The company is likely to release third-quarter 2024 results on Nov. 5. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.63%. The Zacks Consensus Estimate for EPS is expected to improve 33.3% from the year-ago reported figure.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +38.39% and a Zacks Rank #3 at present. The company is expected to release third-quarter 2024 results on Nov. 6.
ACAD’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 42.37%. The Zacks Consensus Estimate for EPS is expected to surge 127.5% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.91% and a Zacks Rank #3 at present. The company is expected to release third-quarter 2024 results on Nov. 7.
BDX’s earnings surpassed estimates in three of the trailing four quarters and met once, the average surprise being 6.24%. The Zacks Consensus Estimate for EPS is expected to increase 10.2% from the year-earlier quarter’s reported figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What's in Store for West Pharmaceutical in Q3 Earnings?
West Pharmaceutical Services (WST - Free Report) is scheduled to release third-quarter 2024 results on Oct. 10, before the opening bell. In the last reported quarter, the company delivered an earnings miss of 14.12%. WST’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 6.44%.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Q3 Estimates
Currently, the Zacks Consensus Estimate for revenues is pegged at $710.2 million, indicating a decline of 5% from the year-ago period’s level. The consensus mark for earnings is pinned at $1.51 per share, indicating a decline of 30.1% year over year.
Factors to Note
During the second quarter, West Pharmaceutical’s Proprietary Products segment sales were hurt by an elevated level of customer destocking across its business units. The trend is likely to have continued in the third quarter, pulling sales down. A weak pharma market and declining sales related to COVID-19 vaccines are expected to have contributed to the decline. The declining trend in the Generic market unit and the Biologics market unit is likely to have continued as well.
Product-wise, sales of Administrative Systems, FluroTec and Westar products, along with Daikyo Crystal Zenith components, are likely to have decreased during the soon-to-be-reported quarter.
WST witnessed a strong uptake of HVP components, which include self-injection, Envision components and NovaPure products in the second quarter. The trend is projected to have continued in the quarter to be reported, partially cushioning the sales decline in the segment.
The company is also expected to have witnessed a gross margin contraction in the aforementioned segment. This was likely due to an unfavorable mix of products sold (stemming from the demand for high-value products), production efficiencies and higher sales prices.
On its second quarter earnings call, WST lowered its top and bottom-line outlook for 2024 by more than 4% and 16%, respectively, as measured by the midpoint of the new and earlier guided ranges.
West Pharmaceutical Services, Inc. Price and EPS Surprise
West Pharmaceutical Services, Inc. price-eps-surprise | West Pharmaceutical Services, Inc. Quote
WST’s Contract-Manufactured Products segment might have aided top-line growth due to expanding customer demand for its services during the quarter.
The company’s business is exposed to foreign currency exchange rate fluctuations, which are likely to have negatively impacted its third-quarter performance. Meanwhile, WST is investing in capacity expansion, especially to support its HVP products. This is likely to have driven cash burn during the soon-to-be-reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for WST this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is -0.16%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #4 (Sell) at present.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Masimo (MASI - Free Report) has an Earnings ESP of +0.40% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is likely to release third-quarter 2024 results on Nov. 5. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.63%. The Zacks Consensus Estimate for EPS is expected to improve 33.3% from the year-ago reported figure.
ACADIA Pharmaceuticals (ACAD - Free Report) has an Earnings ESP of +38.39% and a Zacks Rank #3 at present. The company is expected to release third-quarter 2024 results on Nov. 6.
ACAD’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 42.37%. The Zacks Consensus Estimate for EPS is expected to surge 127.5% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.91% and a Zacks Rank #3 at present. The company is expected to release third-quarter 2024 results on Nov. 7.
BDX’s earnings surpassed estimates in three of the trailing four quarters and met once, the average surprise being 6.24%. The Zacks Consensus Estimate for EPS is expected to increase 10.2% from the year-earlier quarter’s reported figure.